Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

Expert Review of Vaccines

Volumn 3, Issue 4 SUPPL., 2004, Pages

  Gao, Feng ^a,b   Korber, Bette T ^c   Weaver, Eric A ^b   Liao, Hua Xin ^b   Hahn, Beatrice H ^d   Haynes, Barton F ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Consensus; Diversity; Immunogen; Vaccine

Indexed keywords

ANTIGEN; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIGENICITY; B LYMPHOCYTE; GENE SEQUENCE; GENETIC RECOMBINATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; T LYMPHOCYTE; VIRUS GENE; VIRUS ISOLATION; VIRUS TYPING; WILD TYPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENOME, VIRAL; HIV ANTIGENS; HIV-1; HUMANS; SOFTWARE; VARIATION (GENETICS);

EID: 4344660751     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.S161     Document Type: Review

References (78)

1. UNAIDS-WHO. AIDS epidemic update (2003).
2. Stanecki KA. The AIDS Pandemic in the 21th Century. The US Census Bureau (www.census.gov/ipc/prod/wp02/wp02-2.pdf) (2004).
3. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
4. Cao Y, Qin L, Zhang L, Safrit J and Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus Type 1 infection. N. Engl. J. Med. 332, 201-208 (1995).
5. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J. Infect. Dis. 179, 1365-1374 (1999).
6. Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164, 1602-1611 (2000).
7. Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1, 59-64 (1995).
8. Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000). Demonstrates that the when augmented by interleukin (IL)-2/immunoglobulin (Ig), DNA vaccines of SIVMac239 Gag and HIV-1 89.6P Env can control the SHIV 89.6P viral replication to undetectable levels in blood.
9. Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine. Science 292, 69-74 (2001). Demonstrates that the heterologous DNA prime and modified vaccinia Ankara boost strategy with multiple HIV/SIV genes can induce immune responses that control viral replication after SHIV 89.6 challenge.
10. Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002). Demonstrates that the replication incompetent adenovirus Type 5 (Ad5) vector-expressing the SIV Gag protein can exhibit the pronounced attenuation of the SHIV infection.
11. Veazey RS, Shattock RJ, Pope M et al. Prevention of virus transmission to macaque monkeys by a vaginalty applied monoclonal antibody to HIV-1 gp120. Nature Med. 9, 343-346 (2003). Demonstrates that administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from SHIV-162P4 infection through the vagina.
12. Peeters M, Toure-Kane C, Nkengasong JN. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17, 2547-2560 (2003). Reviews extensive genetic diversity and recombination in Africa and discusses its impact on vaccine development.
13. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nature Immunol. 2, 473-475 (2001). Reviews and discusses the important impact of human HLA types and genetic diversity of HIV on AIDS vaccine development
14. Korber B, Foley B, Gaschen B, Kuiken C. Epidemiological and immunological implications of the global variability of HIV-1. In: Retroviral Immunology. Pantaleo G, Walker B (Eds). Humana Press, Inc., NJ, USA, 1-32 (2001).
15. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
16. Gaschen B, Taylor J, Yusim K et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002). Proposes the use of consensus and ancestral viral gene sequences for the induction of broader T-and B-cell immune responses and discusses the advantages of consensus and ancestral sequences over wild-type viral gene sequencess.
17. Gao F, Bhattacharya T, Gaschen B et al. Consensus and Ancestral State HIV Vaccines (Letter). Science 299, 1517-1518 (2003).
18. Nickle DC, Jensen MA, Gottlieb GS et al. Consensus and Ancestral State HIV Vaccines (Letter). Science 299, 1515-1517 (2003). Preposes the COT method as a centralized gene vaccine approach.
19. Novitsky V, Smith UR, Gilben P et al. Human immunodeficiency virus Type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J. Virol. 76, 5435-5451 (2002).
20. Ellenberger DL, Li B, Lupo LD et al. Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 302, 155-163 (2002).
21. Kuiken CL, Foley B, Freed E et al. HIV sequence compendium 2002. Los Alamos, New Mexico: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, USA (2002).
22. Vidal N, Peeters M, Mulanga-Kabeya C et al. Unprecedented degree of human immunodeficiency virus Type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J. Virol. 74, 10498-10507 (2000).
23. Robertson DL, Sharp PM, McCutchan FE and Hahn BH. Recombination in HIV-1. Nature 374, 124-126 (1995).
24. Cbrnelissen M, Kampinga G, Zorgdrager F, Goudsmit J. Human immunodeficiency virus Type 1 subtypes defined by env show high frequency of recombinant gag genes. The UNAIDS Network for HIV Isolation and Characterization. J. Virol. 70, 8209-8212 (1996).
25. Dowling WE, Kim B, Mason CJ et al. Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS 16, 1809-1820 (2002).
26. Hoelscher M, Dowling WE, Sanders-Buell E et al. Detection of HIV-1 subtypes, recombinants and dual infections in east Africa by a multi-region hybridization assay. AIDS 16, 2055-2064 (2002).
27. Hoelscher M, Kim B, Maboko L et al. High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania. AIDS 15, 1461-1470 (2001).
28. Carr JK, Foley BT, Leitner T, Salminen MO, Korber BT, McCutchan F. Reference sequences representing the principal genetic diversity of HIV-1 in the pandemic. In: Human Retroviruses and AIDS 1998: a Compilation and Analysis of Nucleic Acid and Amino Acid Sequence. Korber B, Kuiken C, Foley B et al., (Eds), Los Alamos, New Mexico, USA. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, III-10-III-19 (1998).
29. Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomenclature proposal. Science 288, 55-56 (2000).
30. Bartlett JA, Wasserman SS, Hicks CB et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. AIDS 12, 1291-1300 (1998).
31. Cho MW, Kim YB, Lee MK et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75, 2224-2234 (2001). Demonstrates that administration of multiple subtype B Env proteins can induce broader neutralizing spectrum against a number of subtype B isolates than any single subtype B Env protein.
32. Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ. Immnunogenicity of multiple gene and clade human immunodeficiency virus Type 1 DNA vaccines. J. Virol. 77, 12764-12772 (2003). Demonstrates that a multigene and multiclade vaccine that consists of subtype A, B and C Env and Gag-Pol-Nef can broaden antiviral immune responses without immune interference.
33. Haynes B, Ma B, Montefiori D et al Analysis of HIV-1 subtype B and C envelope third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. J. Virol. (Submitted) 2004
34. Fouts T, Godfrey K, Bobb K et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl Acad. Sci. USA 99, 11842-11847 (2002).
35. ROben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus Type 1. J. Virol. 68, 4821-4828 (1994).
36. Saphire EO, Parren YW, Pantophlet R et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
37. Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
38. Moore JP, McCutchan FE, Poon SW et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus Type 1 by using monoclonal antibodies. J. Virol. 68, 8350-8364 (1994).
39. Moulard M, Phogat SK, Shu Y et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl Acad. Sci. USA 99, 6913-6918 (2002).
40. Trkola A, Pomales AB, Yuan H et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609-6617 (1995).
41. Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus Type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
42. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nature Immunol. 5, 233-236 (2004). Reviews the current challenges and potential new approaches to induce neutralizing antibodies against HIV
43. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389-1393 (1997).
44. Letvin NL, Montefiori DC, Yasutomi Y et al. Potent, protective antiHIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl Acad. Sci. USA 94, 9378-9383 (1997).
45. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus bypassive infusion of neutralizing antibodies. Nature Med. 6, 207-210 (2000). Demonstrates that passive infusion of the most potent combinations of broadly neutralizing antibodies into monkeys can confer the highest level of protection against vaginal exposure to a pathogenic SHIV89.6PD.
46. Desrosiers RC. Prospects for an AIDS vaccine. Nature Med. 10, 221-223 (2004). Reviews the current challenges for vaccine development and appeal for more fundamental basic research for a possible AIDS vaccine.
47. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum immunogenicity in mice. Vaccine 16, 426-435 (1998).
48. Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
49. Hanke T, McMichael A. Preclinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66, 177-181 (1999).
50. Hanke T, Blanchard TJ, Schneider J et al. Immunogenicities of iv. and im. administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus Type 1 in mice. J. Gen. Virol. 79(Pt 1), 83-90 (1998).
51. Korber B, Muldoon M, Theiler J et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000).
52. Yusim K, Kesmir C, Gaschen B et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus Type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 76, 8757-8768 (2002).
53. Korber B, Brander C, Haynes B et al. HIV Molecular Immunology 2002. Los Alamos, New Mexico, USA. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, USA (2002).
54. Gao F, Weaver EA, Lu Z et al. Antigenicity and Immunogenicity of a synthetic HIV-1 group M consensus envelope glycoprotein. (Submitted) (2004).
55. Center RJ, Earl PL, Lebowitz J, Schuck P, Moss B. The human immunodeficiency virus Type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 74, 4448-4455 (2000).
56. Weaver EA, Lu Z, Li Y et al. Immunogenicity of HIV-1 group M consensus Env immunogens. AIDS Vaccine 2003 (Abstract #43).
57. Weaver EA, Lu Z, Li Y et al. Cross-subtype immune responses of HIV-1 group M consensus Env immunogens. The 11th Conference on Retroviruses and Opportunistic Infections (Abstract #164) (2004).
58. Liao HX, Alam M, Mascola J et al. Immunogenicity of Constrained Monoclonal Antibody A32-HIV Env gp120 Complexes Compared to Recombinant HIV-1 gp 120 Envelope Glycoproteins. J. Virol. (In Press) (2004).
59. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science 279, 2105-2106 (1998).
60. + T-cell responses following acute HIV-1 infection. J. Virol. 76, 8690-8701 (2002).
61. +T-cells in primary HIV-1 infection. J. Virol. 77, 6867-6878 (2003).
62. Haynes BF. HIV vaccines: where we are and where we are going. Lancet 348, 933-937 (1996). Reviews the concept of epitope-based vaccines for HIV-1.
63. Ward FE, Tuan S, Haynes B. Analysis of HLA frequencies in population cohorts for design of HLA-based HIV vaccines. In: HIV Molecular Immunology Database 1995. Korber B, Brander C, Walker B et al (Eds), Los Alamos National Laboratory, USA, IV10-IV16 (1995).
64. Yasutomi Y, Koenig S, Woods RM et al. A vaccine-elicited, single viral epitope-specific cytotoxic T-lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69, 2279-2284 (1995).
65. Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415, 335-339 (2002).
66. Barouch DH, Kunstman J, Glowczwskie J et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. J. Virol. 77, 7367-7375 (2003).
67. Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
68. Moore CB, John M, James IR, Christiansen FT, Witt CS and Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443 (2002).
69. Graham BS, Ottinger J, Weinhold KJ et al. Phase I clinical trial of a multivalent HIV-1 peptide vaccine containing B and T epitopes formulated in incomplete Freund's adjuvant. AIDS Vaccine 2001 (Abstract #46) (2001).
70. Bansal A, Sabbaj S, Edwards BH et al. T-cell responses in HIV Type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. AIDS Res. Hum. Retroviruses 19, 1017-1026 (2003).
71. Frahm N, Korber BT, Adams CM et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J. Virol. 78, 2187-2200 (2004).
72. Liao HX, Cianciolo GJ, Staats HF et al. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. Vaccine 20, 2396-2403 (2002).
73. Egan MA, Chong SY, Hagen M et al. A Comparative Evaluation of Nasal and Parenteral Vaccine Adjuvants to Elicit Systemic and Mucosal HIV-1 peptide-specific Humoral Immune Responses in Cynomolgus Macaques. Vacant (In Press) 2004.
74. Connor RI, Sheridan KE, Cetadini D, Choe S and Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621-628 (1997).
75. Shankarappa R, Margolick JB, Gange SJ et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus Type 1 infection. J. Virol. 73, 10489-10502 (1999).
76. Derdeyn CA, Decker J, Bibollet-Ruche F et al. envelope-constrained neutralization-sensitive HIv-1 after heterosexual transmission. Science 303, 2019-2022 (2004).
77. Johnson RP, Trocha A, Buchanan TM, Walker BD, Identification of overlapping HLA class I-restricted cytotoxic T-cell epitopes in a conserved region of the human immunodeficiency virus Type I envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. Exp. Med. 175, 961-971 (1992).
78. Goulder PJ, Reid SW, Price DA et al. Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T-lymphocyte epitopes. Eur. J. Immunol. 27, 1515-1521 (1997).